Clinical trial shows aficamten improves exercise capacity and quality of life in obstructive hypertrophic cardiomyopathy, suggesting it may be an effective treatment.
This video explains key findings from the SEQUOIA-HCM trial, which were published in the New England Journal of Medicine. SEQUOIA-HCM focuses on obstructive hypertrophic cardiomyopathy (or oHCM), a condition where the heart contracts too strongly and the heart muscle is too thick and stiff on the left side, leading to obstructed blood flow out of the heart. Aficamten is a cardiac myosin inhibitor that decreases how strongly the heart contracts, and is being tested in clinical trials as a treatment for oHCM. SEQUOIA-HCM involved 142 people with oHCM who took aficamten and 140 who took a placebo, plus their usual medicine(s). Researchers compared aficamten to placebo in terms of how well it works and how safe it is. After 6 months’ treatment, people who took aficamten had a greater improvement in exercise capacity compared to those who took a placebo. They also had improved quality of life, reduced symptoms, and an improvement in how well their heart worked. People had a similar number of side effects whether they took aficamten or a placebo. These results from SEQUOIA-HCM could mean that aficamten may become a new treatment to improve exercise capacity, symptoms, and quality of life among people with oHCM.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: